Navigation Links
Oncology Metrics and Cureline Announce Joint Marketing Agreement

Access to high quality, fully annotated serum, tissue and blood samples are

available for Genomic and Proteomic Research

DALLAS-FORT WORTH, Texas, Jan. 9 /PRNewswire/ -- Oncology Metrics, a business that develops products and services to help accelerate advancements in the treatment of cancer, and Cureline Inc., a global biosample management company dedicated to innovation in human tissue research, have reached an agreement to collaborate on oncology biospecimen procurement and management. The goal of this collaboration is to facilitate the collection and preservation of high quality pre-treatment and post-treatment samples with maximum efficiency.

Human specimens are used extensively in drug discovery and development for characterization of mutations and expression profiles that define severe diseases such as cancer, asthma, rheumatoid arthritis, diabetes and other conditions, and that could be used for developing personalized therapeutics, vaccines and diagnostics. One of the limiting steps in the research and development process is getting access to well-preserved clinically defined samples from patients with detailed and accurate health records. The collaboration between Oncology Metrics' sample procurement network Cure Pace and Cureline will improve the access of industrial and academic researchers to high quality biospecimens.

Olga Potapova, Ph.D., Founder and CEO of Cureline, views the collaboration as "a unique opportunity to provide to academia and the industry cancer biospecimens collected from diverse ethnic background populations through Cureline's clinical network in Eastern Europe and Asia and through the Oncology Metrics' clinical network in the USA."

Commenting on the collaboration, Warren Dodge, President and CEO of Oncology Metrics said "by leveraging the scientific expertise and access to tissue and our domestic access to serum and fresh whole blood, we become a much better resource for the scientists looking to advance the treatment of cancer."

About Oncology Metrics

Oncology Metrics is a service and data business for the oncology community that develops products and services to help accelerate advancements in the treatment of cancer. Oncology Metrics has built three distinct networks of community-based oncology centers from which it gathers financial and operation information (Oncology Circle), clinical information (Data Direct), and biological specimens (Cure Pace). It accesses and aggregates this information to provide a platform of knowledge-based products and services. The cornerstone of Oncology Metrics' approach is to promote the discovery and adoption of best practice. Oncology Metric's customers include oncology care providers and all organizations involved in the quest to improve cancer diagnosis and treatment.

Oncology Metrics knowledge-based products and services will help providers improve their financial and clinical performance, industry develop better products and services for oncology professionals, and patients receive more effective individualized care.

The Oncology Metrics team is comprised of business and medical professionals with decades of experience in healthcare. Oncology Metrics was founded in 2001 and is based in Dallas-Fort Worth, Texas with an office in the San Francisco Bay Area.

Additional information about Oncology Metrics can be found at Contact: Warren Dodge at 415-454-1338 or

About Cureline, Inc.

Cureline, Inc. is a global biosample management company providing effective solutions for scientifically challenging projects. The company was founded in 2003 by a group of scientists and business development professionals who established the biospecimen repository for SUGEN, Inc. and participated in the development of Sutent(R) (Pfizer Inc).

Cureline is dedicated to innovation in human tissue research and has developed multi-site international collaborations for obtaining, handling and processing of human specimens worldwide. Since its inception, the primary focus of Cureline has been oncology, including solid tumors and hematologic malignancies. Every year Cureline's procurement network expands to new therapeutic areas and new countries and now the Cureline's team conduct projects in inflammation, metabolic, neurological and cardiovascular diseases. Cureline is a preferred provider for biospecimens and custom tissue procurement services for VWR International LLC, a company dedicated to drug discovery and development services.

Additional information about Cureline, Inc. can be found at Contact: Mariana Tran, 1-650-952-6557 or

SOURCE Oncology Metrics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
2. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
3. AG Mednet to Provide Image Network for Southwest Oncology Group
4. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers
5. PRA International to Present Audioconference on Oncology Research - Nov. 8
6. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
7. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
8. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
9. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
10. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
11. VivoMetrics(R) Appoints Howard R. Baker as New President and Chief Executive Officer
Post Your Comments:
(Date:11/25/2015)... --> ... 2020 report analyzes that automating biobanking workflow will ... long-term samples, minimizing manual errors, improving the workflow ... errors such as mislabeling or inaccurate sample barcoding ... a vital role in blood fractionation, DNA extraction, ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... ... 25, 2015 , ... Jessica Richman and Zachary Apte, founders ... initial angel funding process. Now, they are paying it forward to other microbiome ... investments in the microbiome space. In this, they join other successful entrepreneurs-turned-angels ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended September 30, ... Canadian dollars and presented under International Financial Reporting ... ," said Andrew Rae , President ... iCo-008 are not only value enriching for this ...
Breaking Biology Technology:
(Date:10/26/2015)...  Delta ID Inc., a company focused on bringing ... devices, announced its ActiveIRIS® technology powers the iris recognition ... by NTT DOCOMO, INC in Japan ... to include iris recognition technology, after a very successful ... May 2015, world,s first smartphone to have this capability. ...
(Date:10/23/2015)... and GOLETA, California , ... HFES conference, BIOPAC and SensoMotoric Instruments (SMI) announce a ... eye tracking data captured during interactive real-world tasks ... and play integration of their established wearable solutions for ... to synchronize gaze behavior captured with SMI Eye ...
(Date:10/22/2015)... SAN JOSE, Calif., Oct. 22, 2015  Synaptics (NASDAQ: SYNA ... results for its first quarter ended September 30, 2015. ... first quarter of fiscal 2016 grew 66 percent over the comparable ... quarter of fiscal 2016 was $23.8 million, or $0.62 per diluted ... net income for the first quarter of fiscal 2016 grew 39 ...
Breaking Biology News(10 mins):